Zymeworks (NASDAQ:ZYME) Shares Up 4.9% – Time to Buy?

Shares of Zymeworks Inc. (NASDAQ:ZYME – Get Free Report) shot up 4.9% during mid-day trading on Thursday. The stock traded as high as $27.43 and last traded at $27.3120. 226,922 shares were traded during trading, a decline of 71% from the average session volume of 785,557 shares. The stock had previously closed at $26.04.

Wall Street Analyst Weigh In

ZYME has been the subject of a number of research reports. HC Wainwright increased their price objective on Zymeworks from $55.00 to $56.00 and gave the stock a “buy” rating in a report on Tuesday, November 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zymeworks in a report on Thursday, October 15th. TD Cowen increased their target price on Zymeworks from $34.00 to $39.00 and gave the stock a “buy” rating in a research note on Tuesday, November 10th. Jefferies Financial Group reaffirmed a “buy” rating and set a $52.00 price target on shares of Zymeworks in a research report on Friday, October 23rd. Finally, Wolfe Research began coverage on Zymeworks in a report on Thursday, September 17th. They issued an “outperform” rating for the company. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $43.25.

Read Our Latest Report on ZYME

Zymeworks Trading Down 2.7%

The firm has a market capitalization of $1.80 billion, a P/E ratio of 50.27 and a beta of 1.32. The firm has a 50-day moving average of $27.20 and a two-hundred day moving average of $25.57.

Zymeworks (NASDAQ:ZYME – Get Free Report) last released its earnings results on Monday, November 9th. The company reported $2.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.27 by $0.01. The firm had revenue of $512.92 million for the quarter, compared to analysts’ expectations of $227.40 million. Zymeworks had a return on equity of 22.23% and a net margin of 16.10%. The business’s revenue for the quarter was up 828.7% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.26) earnings per share. On average, sell-side analysts anticipate that Zymeworks Inc. will post 1.26 EPS for the current fiscal year.

Zymeworks declared that its Board of Directors has initiated a stock repurchase program on Monday, November 16th that authorizes the company to repurchase $200 million in shares. This buyback authorization authorizes the company to purchase up to 10.9% of its shares through open market purchases. Stock buyback programs are generally a sign that the company’s management believes its stock is undervalued.

Insiders Place Their Bets

In related news, EVP Adam Schayowitz sold 13,832 shares of Zymeworks stock in a transaction that occurred on Friday, October 9th. The shares were sold at an average price of $25.85, for a total transaction of $357,557.20. Following the sale, the executive vice president directly owned 23,205 shares in the company, valued at $599,849.25. This trade represents a 37.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Paul Moore sold 39,741 shares of the business’s stock in a transaction that occurred on Friday, November 13th. The stock was sold at an average price of $26.07, for a total transaction of $1,036,047.87. Following the sale, the insider directly owned 33,756 shares in the company, valued at $880,018.92. The trade was a 54.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 37.73% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Rubric Capital Management LP raised its position in shares of Zymeworks by 21.7% during the first quarter. Rubric Capital Management LP now owns 7,000,000 shares of the company’s stock worth $175,280,000 after acquiring an additional 1,250,000 shares during the last quarter. BlackRock Inc. acquired a new stake in Zymeworks in the second quarter worth $111,122,000. Perceptive Advisors LLC increased its stake in Zymeworks by 7.6% in the first quarter. Perceptive Advisors LLC now owns 3,510,078 shares of the company’s stock valued at $87,892,000 after purchasing an additional 248,228 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Zymeworks by 20.5% during the third quarter. Assenagon Asset Management S.A. now owns 1,508,069 shares of the company’s stock valued at $39,949,000 after purchasing an additional 256,042 shares during the period. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Zymeworks by 102.7% during the third quarter. Goldman Sachs Group Inc. now owns 954,409 shares of the company’s stock valued at $25,282,000 after purchasing an additional 483,587 shares during the period. 92.89% of the stock is owned by institutional investors and hedge funds.

About Zymeworks

(Get Free Report)

Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.

Recommended Stories

Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.